FindTrial
Sign In

Effect of recombinant erythropoietin in covid-19 patients.

Comparison of outcome in Coronavirus disease 2019 (COVID-19) pneumonia patients with or without recombinant erythropoietin (r-EPO) â?? a prospective randomized controlled study.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/11/028959
Enrollment
40
Registered
2020-11-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: J22- Unspecified acute lower respiratory infection

Interventions

Intervention1: recombinant erythropoietin (r-EPO)in addition to standard care.: In 20 moderate to severely diseased patients who require ventilatory support(NIV/IV), 4000IU of r-EPO in addition to sta

Sponsors

All India Institute Of Medical Sciences New Delhi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: sars-cov-2 positive patients. moderate to severe disease who require non-invasive or invasive ventilation.

Exclusion criteria

Exclusion criteria: patients relative refusal. terminal end-organ failure (renal, liver, cardiac, cns) thrombocytosis. concomitant potential serious infections.

Design outcomes

Primary

MeasureTime frame
Deescalation from mechanical ventilation and mortality benefit.Timepoint: 02 weeks—

Secondary

MeasureTime frame
Improvement in clinical status, length of icu and hospital stay, sero-conversion rate,Timepoint: 02 weeks—

Countries

India

Contacts

Public Contactashutosh kumar singh

AIIMS NEW DELHI

anjantrikha@gmail.com9810977901

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026